Cover Image
市場調查報告書

癌症治療的基因學市場分析:各產品 (設備、消耗品、服務) 、各用途 (診斷、個人化醫療、藥物研發&開發、研究) 、各技術、各最終用途,及至2022年的市場區隔預測

Genomics In Cancer Care Market Analysis By Product (Instruments, Consumables, Services), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By Technology, By End-use And Segment Forecasts To 2022

出版商 Grand View Research, Inc. 商品編碼 355225
出版日期 內容資訊 英文 80 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症治療的基因學市場分析:各產品 (設備、消耗品、服務) 、各用途 (診斷、個人化醫療、藥物研發&開發、研究) 、各技術、各最終用途,及至2022年的市場區隔預測 Genomics In Cancer Care Market Analysis By Product (Instruments, Consumables, Services), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By Technology, By End-use And Segment Forecasts To 2022
出版日期: 2016年02月07日 內容資訊: 英文 80 Pages
簡介

全球癌症治療的基因學市場,預計至2022年達到92億2,000萬美元。由於癌症的罹患率上升與診斷,治療的次世代定序的引進,將加速市場未來的成長機會。今後,預計成本效益的高正確的診斷藥的需求也高漲。

本報告提供全球癌症治療的基因學市場現狀與至2022年的成長預測,各產品、各用途、各技術、各最終用途趨勢,及主要企業的簡介等彙整。

第1章 調查方法與調查範圍

第2章 摘要整理

第3章 產業預測

  • 市場區隔
  • 市場規模與成長預測
  • 市場趨勢
    • 促進要素
    • 阻礙要素
  • 市場機會
  • 產業分析:波特
  • PESTEL分析

第4章 各產品市場預測

  • 各產品收益佔有率
  • 設備
  • 消耗品及試劑
  • 服務

第5章 各用途預測

  • 各用途收益佔有率
  • 診斷
  • 個人化醫療
  • 藥物研發、開發
  • 研究

第6章 各技術市場預測

  • 各技術收益佔有率
  • 基因測序
  • 聚合酵素鏈鎖反應 (PCR)
  • 微陣列
  • 核酸開採及煉製
  • 其他 (流式細胞技術,生物資訊學)

第7章 各最終用途預測

  • 各最終用途收益佔有率
  • 醫院
  • 研究機關
  • 學術機構
  • 其他

第8章 各地區預測

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第9章 競爭環境

  • Illumina Inc
  • Agilent Technologies
  • Roche Diagnostics
  • Cancer Genetics Inc
  • Bio-Rad Laboratories
  • Sigma Aldrich
  • Qiagen
  • Perkin Elmer
  • Affymetrix
  • BGI
  • Life technologies
  • GE Healthcare
  • Pacific Biosciences
  • Quest Diagnostics
  • Myriad Genetics
  • Luminex
  • Abbott Molecular
  • Beckman Coulter, Inc
  • Oxford Gene Technology Ltd.

圖表

目錄
Product Code: 978-1-68038-717-9

Global genomics in cancer care market is expected to reach USD 9.22 billion by 2022, according to a new report by Grand View Research, Inc. Increasing prevalence of cancer coupled with adoption of next generation sequencing for the diagnosis & treatment is expected to fuel the market with future growth opportunities. Increasing incidences of cancer triggers the demand for cost effective and accurate diagnostics in coming years.

In addition, increasing demand for personalized medicines in molecular characterization of cancer to identify therapeutic targets is the factor attributing towards the market growth. Similarly, factors such as cost reduction in genome sequencing, growing healthcare expenditure levels and development of effective diagnostics & therapeutic procedures for cancer are responsible for the potential growth of genomics in cancer care.

Further key findings from the study suggest:

Instrument segment dominated the overall market in terms of revenue share as of 2014 and accounted for 33.4% of market owing to high cost associated with it. Whereas, consumables are most widely used product segment in genome testing as they are indispensible component and frequently required to perform the test.

Demand for services such as next generation sequencing, PCR and other such as cancer risk management & genetic testing are expected to grow over the forecast period due to increasing outsourcing activities to perform genome analysis. High cost of performing genetic tests and growing awareness pertaining to associated benefits with the use of these technologies are high impact rendering drivers for this segment.

Drug discovery and development segment is expected to show lucrative CAGR of 17.6% during the forecast period owing to increasing demand for effective treatment for cancer and growing investment in biomedicines by manufacturers for the development of novel products.

Genome sequencing held the dominant share of technology segment as it is most prominently used for diagnosis due to associate benefits such as faster and accurate method. It is expected to show significant growth rate of 17.5% in coming years owing to remarkable decrease in the cost for genome sequencing and increasing adoption rates.

The cancer research segment held the largest share of 34.1% in 2014 due to increasing demand for faster & accurate diagnostic methods to treat variety of cancer. Other use such as commercial adoption of genetic testing is expected to be fastest growing segment owing to increasing demand of cancer genomic testing to fulfill unmet needs in healthcare sector.

Some key players operating in this market include Beckman Coulter Inc., Illumina, Inc, Affymetrix, Roche Diagnostics, Agilent Technologies, Cancer Genetics Inc., Danaher Corporation, Bio-Rad Labs, Pacific Biosciences, Quest Diagnostics, Sigma Aldrich, Luminex, Thermo Fisher scientific, Oxford Gene Technology., PerkinElmer, Qiagen, and GE Healthcare.

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research scope & assumptions
  • 1.3. List of data sources

Chapter 2. Executive Summary

  • 2.1. Genomics in cancer care- Industry Snapshot And Key Buying Criteria, 2012-2022

Chapter 3. Genomics In Cancer Care Industry Outlook

  • 3.1. Genomics in cancer care market segmentation
  • 3.2. Genomics in cancer care market size and growth prospects
  • 3.3. Genomics in cancer care market dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Key opportunities prioritized
  • 3.5. Industry Analysis - Porter's
  • 3.6. Genomics in cancer care market PESTEL analysis, 2014

Chapter 4. Genomics In Cancer Care Product Outlook

  • 4.1. Genomics in cancer care market share by product, 2014 & 2022
  • 4.2. Instruments
    • 4.2.1. Instruments market, 2012-2020 (USD Million)
  • 4.3. Consumables & reagents
    • 4.3.1. Consumables & reagents market, 2012 - 2020 (USD Million)
  • 4.4. Services
    • 4.4.1. Services market estimates and forecasts, 2012 f 2022 (USD Million)

Chapter 5. Genomics In Cancer Care Application Outlook

  • 5.1. Genomics in cancer care revenue share by application, 2013 & 2020
  • 5.2. Diagnostics
    • 5.2.1. Market estimates and forecasts, 2012 - 2020 (USD Million)
  • 5.3. Personalized medicine
    • 5.3.1. Market estimates and forecasts, 2012 - 2020 (USD Million)
  • 5.4. Drug discovery & development
      • 5.4.1.Market estimates and forecasts, 2012 - 2020 (USD Million)
  • 5.5. Research
    • 5.5.1. Market estimates and forecasts, 2012 - 2020 (USD Million))

Chapter 6. Genomics In Cancer Care Technology Outlook

  • 6.1. Genomics in cancer care revenue share by technology, 2013& 2020
  • 6.2. Genome sequencing
    • 6.2.1. Genome sequencing market estimates and forecasts, 2012 - 2020 (USD Million)
  • 6.3. Polymerase chain reaction (PCR)
    • 6.3.1. PCR market estimates and forecasts, 2012 - 2020 (USD Million)
  • 6.4. Microarray
    • 6.4.1. Microarray market estimates and forecasts, 2012 - 2020 (USD Million)
  • 6.5. Nucleic acid extraction and purification
    • 6.5.1. Nucleic acid extraction and purification market estimates and forecasts, 2012 - 2020 (USD Million)
  • 6.6. Other (Flow cytometry, Bioinformatics)
    • 6.6.1. Other market estimates and forecasts, 2012 - 2020 (USD Million)

Chapter 7. Genomics In Cancer Care End-use Outlook

  • 7.1. Genomics in cancer care revenue share by end-use, 2013& 2020
  • 7.2. Hospitals
    • 7.2.1. Hospitals market estimates and forecasts, 2012 - 2020 (USD Million)
  • 7.3. Research institutes
    • 7.3.1. Research institutes market estimates and forecasts, 2012 - 2020 (USD Million)
  • 7.4. Academic institutes
    • 7.4.1. Academic institutes market estimates and forecasts, 2012 - 2020 (USD Million)
  • 7.5. Others (diagnostic labs, commercial organizations & physician office)
    • 7.5.1. Other market estimates and forecasts, 2012 - 2020 (USD Million)

Chapter 8. Genomics In Cancer Care Regional Outlook

  • 8.1. Genomics in cancer care market share by region, 2014 & 2022
  • 8.2. North America
    • 8.2.1. North America Market Estimates and Forecasts, by Application, 2012 - 2022 (USD Million)
      • 8.2.1.1. U.S. Market Estimates and Forecasts
      • 8.2.1.2. Canada Market Estimates and Forecasts
  • 8.3. Europe
    • 8.3.1. Europe Market Estimates and Forecasts, by Application, 2012 - 2022 (USD Million)
      • 8.3.1.1. Germany Market Estimates and Forecasts
      • 8.3.1.2. UK Market Estimates and Forecasts
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
      • 8.4.1.1. Japan Market Estimates and Forecasts
      • 8.4.1.2. China Market Estimates and Forecasts
      • 8.4.1.3. India Market Estimates and Forecasts
  • 8.5. Latin America
    • 8.5.1. Latin America Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
      • 8.5.1.1. Brazil Market Estimates and Forecasts
      • 8.5.1.2. Mexico Market Estimates and Forecasts
  • 8.6. MEA
    • 8.6.1. MEA Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
      • 8.6.1.1. South Africa Estimates and Forecasts

Chapter 9. Competitive Landscape

  • 9.1. Illumina Inc
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Strategic Initiatives
  • 9.2. Agilent Technologies
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Strategic Initiatives
  • 9.3. Roche Diagnostics
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Strategic Initiatives
  • 9.4. Cancer Genetics Inc
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Strategic Initiatives
  • 9.5. Bio-Rad Laboratories
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Strategic Initiatives
  • 9.6. Sigma Aldrich
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Strategic Initiatives
  • 9.7. Qiagen
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Strategic Initiatives
  • 9.8. Perkin Elmer
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Strategic Initiatives
  • 9.9. Affymetrix
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Strategic Initiatives
  • 9.10. BGI
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Strategic Initiatives
  • 9.11. Life technologies
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Strategic Initiatives
  • 9.12. GE Healthcare
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Strategic Initiatives
  • 9.13. Pacific Biosciences
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Strategic Initiatives
  • 9.14. Quest Diagnostics
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Strategic Initiatives
  • 9.15. Myriad Genetics
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Strategic Initiatives
  • 9.16. Luminex
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Strategic Initiatives
  • 9.17. Abbott Molecular
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Strategic Initiatives
  • 9.18. Beckman Coulter, Inc
    • 9.18.1. Company Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Strategic Initiatives
  • 9.19. Oxford Gene Technology Ltd.
    • 9.19.1. Company Overview
    • 9.19.2. Financial Performance
    • 9.19.3. Product Benchmarking
    • 9.19.4. Strategic Initiatives

List of Tables

  • TABLE 1: Genomics in cancer care market- Industry Snapshot & Key Buying Criteria, 2012 - 2022
  • TABLE 2: Global genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 3: Global genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 4: Global genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 5: Global genomics in cancer care market, by end-use, 2012 - 2022(USD Million)
  • TABLE 6: Global Genomics in cancer care market, by region, 2012 - 2022 (USD Million)
  • TABLE 7: Genomics in cancer care- Key market driver analysis
  • TABLE 8: Genomics in cancer care market - Key market restraint analysis
  • TABLE 9: North America genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 10: North America genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 11: North America genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 12: North America genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 13: U.S. genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 14: U.S. genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 15: U.S. genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 16: U.S. genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 17: Canada genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 18: Canada genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 19: Canada genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 20: Canada genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 21: Europe genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 22: Europe genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 23: Europe genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 24: Europe genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 25: UK genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 26: UK genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 27: UK genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 28: UK genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 29: Germany genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 30: Germany genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 31: Germany genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 32: Germany genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 33: Asia Pacific genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 34: Asia Pacific genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 35: Asia Pacific genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 36: Asia Pacific genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 37: Japan genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 38: Japan genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 39: Japan genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 40: Japan genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 41: China genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 42: China genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 43: China genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 44: China genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 45: India genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 46: India genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 47: India genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 48: India genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 49: Latin America genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 50: Latin America genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 51: Latin America genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 52: Latin America genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 53: Mexico genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 54: Mexico genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 55: Mexico genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 56: Mexico genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 57: Brazil genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 58: Brazil genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 59: Brazil genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 60: Brazil genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 61: MEA genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 62: MEA genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 63: MEA genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 64: MEA genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 65: South Africa genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 66: South Africa genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 67: South Africa genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 68: South Africa genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)

List of Figures

  • FIG. 1: Genomics in canecr care: Market segmentation
  • FIG. 2: Genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 3: Genomics in cancer care: Market dynamics
  • FIG. 4: Key opportunities prioritized
  • FIG. 5: Genomics in cancer care market Porter's analysis
  • FIG. 6: Genomics in cancer care market PESTEL analysis
  • FIG. 7: Genomics in cancer care technology development analysis, 2014 & 2022
  • FIG. 8: Genomics in cancer care revenue share by product, 2014 & 2022
  • FIG. 9: Instruments market, 2012 - 2022 (USD Million)
  • FIG. 10: Consumables market, 2012 - 2022 (USD Million)
  • FIG. 11: Services market, 2012 - 2022 (USD Million)
  • FIG. 12: Genomics in cancer caremarket share by application, 2014 & 2022
  • FIG. 13: Diagnostics market, 2012 - 2022 (USD Million)
  • FIG. 14: Personalized medicine market, 2012 - 2022 (USD Million)
  • FIG. 15: Drug discovery & development market, 2012 - 2022 (USD Million)
  • FIG. 16: Research market, 2012 - 2022 (USD Million)
  • FIG. 17: Genomics in cancer caremarket share by technology, 2014 & 2022
  • FIG. 18: Genome sequencing market, 2012 - 2022 (USD Million)
  • FIG. 19: PCR market, 2012 - 2022 (USD Million)
  • FIG. 20: Microarrays market, 2012 - 2022 (USD Million)
  • FIG. 21: Nuclic acid extraction & purification market, 2012 - 2022 (USD Million)
  • FIG. 22: Other market, 2012 - 2022 (USD Million)
  • FIG. 23: Genomics in cancer care revenue share by end-use, 2014 & 2022
  • FIG. 24: Hospitals market, 2012 - 2022 (USD Million)
  • FIG. 25: Research institutes market, 2012 - 2022 (USD Million)
  • FIG. 26: Academic institutes market, 2012 - 2022 (USD Million)
  • FIG. 27: Other market, 2012 - 2022 (USD Million)
  • FIG. 28: North America genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 29: U.S. genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 30: Canada genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 31: Europe genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 32: UK genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 33: Germany genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 34: Asia Pacific genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 35: Japan genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 36: China genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 37: India genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 38: Latin America genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 39: Mexico genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 40: Brazil genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 41: MEA genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 42: South Africa genomics in cancer care market, 2012 - 2022 (USD Million)
Back to Top